Rallybio Corporation, a clinical-stage biotechnology firm, announced the commencement of dosing in their Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study for RLYB116. This study is targeted at addressing immune platelet transfusion refractoriness $(PTR.AU)$ and refractory antiphospholipid syndrome (APS), two hematologic conditions with significant unmet medical needs. The study aims to assess the safety and efficacy of RLYB116, a once-weekly, subcutaneously injected C5 inhibitor, in achieving complete and sustained complement inhibition. Data from the study's Cohort 1 are expected in the third quarter of 2025, with results from Cohort 2 anticipated in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.